RU2003107564A - ANTIBODIES TO HUMAN IL-1BETA - Google Patents

ANTIBODIES TO HUMAN IL-1BETA

Info

Publication number
RU2003107564A
RU2003107564A RU2003107564/13A RU2003107564A RU2003107564A RU 2003107564 A RU2003107564 A RU 2003107564A RU 2003107564/13 A RU2003107564/13 A RU 2003107564/13A RU 2003107564 A RU2003107564 A RU 2003107564A RU 2003107564 A RU2003107564 A RU 2003107564A
Authority
RU
Russia
Prior art keywords
amino acid
ser
fragment
encodes
cdr2
Prior art date
Application number
RU2003107564/13A
Other languages
Russian (ru)
Other versions
RU2286351C2 (en
Inventor
Германн Грам
Франко Э. ДИ-ПАДОВА
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0020685.4A external-priority patent/GB0020685D0/en
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2003107564A publication Critical patent/RU2003107564A/en
Application granted granted Critical
Publication of RU2286351C2 publication Critical patent/RU2286351C2/en

Links

Claims (11)

1. IL-1β-связывающая молекула, которая содержит антигенсвязывающий центр антитела, включающий по меньшей мере одну вариабельную область тяжелой цепи (VH) иммуноглобулина, которая включает расположенные в указанной последовательности гипервариабельные участки CDR1, CDR2 и CDR3, где CDR1 имеет аминокислотную последовательность Val-Tyr-Gly-Met-Asn, CDR2 имеет аминокислотную последовательность Ile-Ile-Trp-Tyr-Asp-Gly-Asp-Asn-Gln-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly и CDR3 имеет аминокислотную последовательность Asp-Leu-Arg-Thr-Gly-Pro, и ее непосредственные эквиваленты.1. IL-1β-binding molecule, which contains the antigen-binding center of the antibody, comprising at least one variable region of the heavy chain (V H ) of the immunoglobulin, which includes located in the indicated sequence of the hypervariable regions of CDR1, CDR2 and CDR3, where CDR1 has the amino acid sequence Val Tyr-Gly-Met-Asn, CDR2 has the amino acid sequence Ile-Ile-Trp-Tyr-Asp-Gly-Asp-Asn-Gln-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly, and CDR3 has the amino acid the sequence Asp-Leu-Arg-Thr-Gly-Pro, and its immediate equivalents. 2. IL-1β-связывающая молекула, включающая по меньшей мере одну вариабельную область легкой цепи (VL) иммуноглобулина, которая состоит из расположенных в указанной последовательности гипервариабельных участков CDR1’, CDR2’ и CDR3’, где CDR1’ имеет аминокислотную последовательность Arg-Ala-Ser-Gln-Ser-Ile-Gly-Ser-Ser-Leu-His, CDR2’ имеет аминокислотную последовательность Ala-Ser-Gln-Ser-Phe-Ser и CDR3’ имеет аминокислотную последовательность His-Gln-Ser-Ser-Ser-Leu-Pro, и ее непосредственные эквиваленты.2. IL-1β-binding molecule, comprising at least one variable region of the immunoglobulin light chain (V L ), which consists of the hypervariable regions CDR1 ', CDR2' and CDR3 'located in the indicated sequence, where CDR1' has the amino acid sequence Arg- Ala-Ser-Gln-Ser-Ile-Gly-Ser-Ser-Leu-His, CDR2 'has the amino acid sequence Ala-Ser-Gln-Ser-Phe-Ser and CDR3' has the amino acid sequence His-Gln-Ser-Ser- Ser-Leu-Pro, and its immediate equivalents. 3. IL-1β-связывающая молекула, которая включает вариабельные области и тяжелой (VH) и легкой цепи (VL), при этом указанная IL-1β-связывающая молекула содержит по меньшей мере один антигенсвязывающий центр антитела, включающий а) вариабельную область тяжелой цепи (VH) иммуноглобулина, которая включает расположенные в указанной последовательности гипервариабельные участки CDR1, CDR2 и CDR3, где CDR1 имеет аминокислотную последовательность Val-Tyr-Gly-Met-Asn, CDR2 имеет аминокислотную последовательность Ile-Ile-Trp-Tyr-Asp-Gly-Asp-Asn-Gln-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly и CDR3 имеет аминокислотную последовательность Asp-Leu-Arg-Thr-Gly-Pro, и б) вариабельную область легкой цепи (VL) иммуноглобулина, которая состоит из расположенных в указанной последовательности гипервариабельных участков CDR1’, CDR2’ и CDR3’, где CDR1’ имеет аминокислотную последовательность Arg-Ala-Ser-Gln-Ser-Ile-Gly-Ser-Ser-Leu-His, CDR2’ имеет аминокислотную последовательность Ala-Ser-Gln-Ser-Phe-Ser и CDR3’ имеет аминокислотную последовательность Gln-Gln-Arg-Sar-Asn-Trp-Met-Phe-Pro, и ее непосредственные эквиваленты.3. IL-1β-binding molecule, which includes the variable regions of both the heavy (V H ) and light chains (V L ), wherein said IL-1β-binding molecule contains at least one antigen-binding center of the antibody, comprising a) a variable region the immunoglobulin heavy chain (V H ), which includes the hypervariable regions of CDR1, CDR2 and CDR3 located in the indicated sequence, where CDR1 has the amino acid sequence Val-Tyr-Gly-Met-Asn, CDR2 has the amino acid sequence Ile-Ile-Trp-Tyr-Asp -Gly-Asp-Asn-Gln-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly and CDR3 has an amino acid acid sequence Asp-Leu-Arg-Thr- Gly-Pro, and b) a light chain variable region (V L) immunoglobulin, which comprises in sequence hypervariable regions CDR1 ', CDR2' and CDR3 ', wherein CDR1' having the amino acid the sequence Arg-Ala-Ser-Gln-Ser-Ile-Gly-Ser-Ser-Leu-His, CDR2 'has the amino acid sequence Ala-Ser-Gln-Ser-Phe-Ser and CDR3' has the amino acid sequence Gln-Gln-Arg -Sar-Asn-Trp-Met-Phe-Pro, and its immediate equivalents. 4. IL-1β-связывающая молекула по пп.1, 2 или 3, представляющая собой человеческое антитело.4. IL-1β-binding molecule according to claims 1, 2 or 3, which is a human antibody. 5. IL-1β-связывающая молекула, которая включает по меньшей мере один антигенсвязывающий центр антитела, включающий либо первый домен, аминокислотная последовательность которого практически идентична последовательности, представленной в Seq. Id. No. 1, которая начинается с аминокислоты в положении 1 и заканчивается аминокислотой в положении 118, либо описанный выше первый домен и второй домен, аминокислотная последовательность которого практически идентична последовательности, представленной в Seq. Id. No. 2, которая начинается с аминокислоты в положении 1 и заканчивается аминокислотой в положении 107.5. IL-1β-binding molecule, which includes at least one antigennegative center of the antibody, including either the first domain, the amino acid sequence of which is almost identical to the sequence presented in Seq. Id. No. 1, which begins with the amino acid at position 1 and ends with the amino acid at position 118, or the first domain and the second domain described above, the amino acid sequence of which is almost identical to the sequence shown in Seq. Id. No. 2, which begins with the amino acid at position 1 and ends with the amino acid at position 107. 6. Первая конструкция ДНК, которая кодирует тяжелую цепь или ее фрагмент, включающая а) первый фрагмент, который кодирует вариабельную область, содержащую альтернативные каркасный и гипервариабельные участки, где гипервариабельные участки состоят из последовательно расположенных CDR1, CDR2 и CDR3, аминокислотные последовательности которых представлены в Seq. Id. No. 1, этот первый фрагмент начинается с кодона, который кодирует первую аминокислоту вариабельной области, и заканчивается кодоном, который кодирует последнюю аминокислоту вариабельной области, и б) второй фрагмент, кодирующий константную область тяжелой цепи или ее фрагмент, который начинается с кодона, который кодирует первую аминокислоту константной области тяжелой цепи, и заканчивается кодоном, который кодирует последнюю аминокислоту константной области или ее фрагмента, после которого расположен стоп-кодон.6. The first DNA construct that encodes a heavy chain or fragment thereof, comprising a) a first fragment that encodes a variable region containing alternative framework and hypervariable regions, where the hypervariable regions consist of sequentially arranged CDR1, CDR2 and CDR3, the amino acid sequences of which are presented in Seq. Id. No. 1, this first fragment begins with a codon that encodes the first amino acid of the variable region, and ends with a codon that encodes the last amino acid of the variable region, and b) a second fragment encoding a constant region of the heavy chain or a fragment that begins with a codon that encodes the first the amino acid of the constant region of the heavy chain, and ends with a codon that encodes the last amino acid of the constant region or its fragment, after which the stop codon is located. 7. Вторая конструкция ДНК, которая кодирует легкую цепь или ее фрагмент, включающая а) первый фрагмент, который кодирует вариабельную область, содержащую альтернативные каркасный участок и гипервариабельные участки, где гипервариабельные участки представляют собой CDR1’, CDR2’ и CDR3’, аминокислотные последовательности которых представлены в Seq. Id. No. 2, этот первый фрагмент начинается с кодона, который кодирует первую аминокислоту вариабельной области и заканчивается кодоном, который кодирует последнюю аминокислоту вариабельной области, и б) второй фрагмент, кодирующий константную область легкой цепи или ее фрагмент, который начинается с кодона, кодирующего первую аминокислоту константной области легкой цепи, и заканчивающуюся кодоном, который кодирует последнюю аминокислоту константной области или ее фрагмента, после которого расположен стоп-кодон.7. A second DNA construct that encodes a light chain or fragment thereof, comprising a) a first fragment that encodes a variable region containing alternative framework region and hypervariable regions, where the hypervariable regions are CDR1 ', CDR2' and CDR3 ', the amino acid sequences of which presented in Seq. Id. No. 2, this first fragment begins with a codon that encodes the first amino acid of the variable region and ends with a codon that encodes the last amino acid of the variable region, and b) a second fragment encoding a constant region of the light chain or a fragment that begins with a codon encoding the first amino acid constant region of the light chain, and ending with a codon that encodes the last amino acid of the constant region or its fragment, after which the stop codon is located. 8. Экспрессионный вектор, обладающий способностью к репликации в линии прокариотических или эукариотических клеток, который содержит по меньшей мере одну конструкцию ДНК по п.6 или 7.8. An expression vector capable of replication in a line of prokaryotic or eukaryotic cells, which contains at least one DNA construct according to claim 6 or 7. 9. Способ получения IL-1β-связывающей молекулы, который предусматривает (I) культивирование организма, трансформированного экспрессионным вектором по п.8, и (II) выделение IL-1β-связывающей молекулы из культуры.9. A method for producing an IL-1β-binding molecule, which comprises (I) culturing an organism transformed with the expression vector of claim 8, and (II) isolating the IL-1β-binding molecule from the culture. 10. Антитело к IL-1β, которое обладает способностью к специфическому связыванию с антигенным эпитопом зрелого человеческого IL-1β, который содержит петлю, несущую остаток Glu 64, и которое обладает способностью ингибировать связывание IL-1β с его рецептором.10. An antibody to IL-1β, which has the ability to specifically bind to the antigenic epitope of mature human IL-1β, which contains a loop carrying the residue of Glu 64, and which has the ability to inhibit the binding of IL-1β to its receptor. 11. I) Применение антитела к IL-1β по п.10 для лечения опосредуемого IL-1 заболевания или нарушения, II) способ лечения опосредуемого IL-1 заболевания или нарушения у пациента, предусматривающий введение пациенту эффективного количества антитела по п.10, III) фармацевтическая композиция, содержащая антитело к IL-1β по п.10 в сочетании с фармацевтически приемлемым эксципиентом, разбавителем или носителем, и IV) применение антитела к IL-1β по п.10 для приготовления лекарственного средства, предназначенного для лечения опосредуемого IL-1 заболевания или нарушения.11. I) The use of antibodies to IL-1β of claim 10 for the treatment of IL-1 mediated disease or disorder; II) a method for treating IL-1 mediated disease or disorder in a patient, comprising administering to the patient an effective amount of the antibody of claim 10, III ) a pharmaceutical composition comprising an anti-IL-1β antibody of claim 10 in combination with a pharmaceutically acceptable excipient, diluent or carrier, and IV) the use of an anti-IL-1β antibody of claim 10 for the preparation of a medicament for the treatment of IL-1 mediated disease or broken and I.
RU2003107564/13A 2000-08-22 2001-08-20 HUMAN ANTIBODIES TO IL-β1 RU2286351C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0020685.4A GB0020685D0 (en) 2000-08-22 2000-08-22 Organic compounds
GB0020685.4 2000-08-22

Publications (2)

Publication Number Publication Date
RU2003107564A true RU2003107564A (en) 2004-07-20
RU2286351C2 RU2286351C2 (en) 2006-10-27

Family

ID=9898090

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003107564/13A RU2286351C2 (en) 2000-08-22 2001-08-20 HUMAN ANTIBODIES TO IL-β1

Country Status (37)

Country Link
US (3) US7446175B2 (en)
EP (1) EP1313769B2 (en)
JP (2) JP4271936B2 (en)
KR (2) KR20080056316A (en)
CN (1) CN100547003C (en)
AR (1) AR035581A1 (en)
AT (1) ATE396206T1 (en)
AU (2) AU9549001A (en)
BE (1) BE2009C057I2 (en)
BR (1) BR0113420A (en)
CA (1) CA2420231C (en)
CY (2) CY1108779T1 (en)
CZ (1) CZ304470B6 (en)
DE (2) DE122009000078I1 (en)
DK (1) DK1313769T4 (en)
EC (1) ECSP034490A (en)
ES (1) ES2305110T5 (en)
FR (1) FR09C0062I2 (en)
GB (1) GB0020685D0 (en)
HK (1) HK1061403A1 (en)
HU (2) HU228159B1 (en)
IL (2) IL154465A0 (en)
LU (1) LU91624I2 (en)
MX (1) MXPA03001590A (en)
MY (1) MY130248A (en)
NL (1) NL300427I2 (en)
NO (3) NO332609B1 (en)
NZ (2) NZ524199A (en)
PE (1) PE20020319A1 (en)
PL (1) PL212480B1 (en)
PT (1) PT1313769E (en)
RU (1) RU2286351C2 (en)
SI (1) SI1313769T2 (en)
SK (1) SK288089B6 (en)
TW (1) TWI321568B (en)
WO (1) WO2002016436A2 (en)
ZA (1) ZA200301275B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2518295C2 (en) * 2005-06-21 2014-06-10 Ксома Текнолоджи Лтд. IL-1beta-BINDING ANTIBODIES AND FRAGMENTS THEREOF

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001297702A1 (en) * 2000-11-08 2002-10-15 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
WO2004022718A2 (en) 2002-09-06 2004-03-18 Amgen, Inc. Therapeutic human anti-il-1r1 monoclonal antibody
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
EP1590369B1 (en) * 2003-01-24 2016-03-16 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
ES2523147T3 (en) * 2004-02-26 2014-11-21 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
AU2012213934B9 (en) * 2005-01-26 2013-07-25 Amgen Fremont Inc. Antibodies against interleukin-1 beta
CA2590164A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
GB0509512D0 (en) * 2005-05-10 2005-06-15 Novartis Ag Organic compounds
JP2009511545A (en) * 2005-10-14 2009-03-19 ノボ・ノルデイスク・エー／エス Treatment of diabetes using IL-1 inhibitors
CN102861332A (en) * 2005-10-26 2013-01-09 诺瓦提斯公司 Novel use of il-1beta compounds
KR20110079922A (en) * 2006-04-14 2011-07-11 노파르티스 아게 Use of il-1 antibodies for treating ophthalmic disorders
CA2673592C (en) 2006-12-20 2014-03-25 Xoma Technology Ltd. Methods for the treatment of il-1.beta. related diseases
CL2008001071A1 (en) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Method to obtain penta-specific antibody against human il-8 / cxcl8, gro-alpha / cxcl1, gro-beta / cxcl2), gro-gamma / cxcl3 and ena-78 / cxcl5; penta-specific antibody; production process of the same; vector, hybridoma or cella that comprises it; pharmaceutical composition; use to treat copd, other diseases.
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
US8282922B2 (en) * 2007-05-29 2012-10-09 Novartis Ag Method of treating an auto-inflammatory syndrome with a human IL-1β binding antibody
ES2527326T3 (en) * 2007-12-20 2015-01-22 Xoma (Us) Llc Methods for the treatment of gout
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
MX2010013236A (en) 2008-06-03 2011-02-24 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
PT2293816E (en) * 2008-06-06 2013-02-13 Xoma Technology Ltd Methods for the treatment of rheumatoid arthritis
MX2010014574A (en) 2008-07-08 2011-04-27 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof.
JP2012502059A (en) * 2008-09-05 2012-01-26 ゾーマ テクノロジー リミテッド Methods for treating or preventing IL-1β related diseases
KR20110071011A (en) * 2008-10-20 2011-06-27 아보트 러보러터리즈 Antibodies that bind to il-18 and methods of purifying the same
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US20130122008A1 (en) * 2009-05-06 2013-05-16 Novartis Ag Anti-IL 1- ß Antibody Combination Therapy
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
PE20121530A1 (en) * 2009-09-01 2012-12-22 Abbvie Inc IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN
US8716450B2 (en) * 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN102596995B (en) 2009-10-26 2015-08-12 弗·哈夫曼-拉罗切有限公司 For the production of the method for glycosylated immunoglobulins
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
BR112012028557A2 (en) 2010-05-07 2019-09-24 Xoma Technology Ltd. use of an anti-yl-1b antibody or binding fragments thereof.
RU2013109275A (en) 2010-08-03 2014-09-10 Эббви Инк. IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION
KR20130139884A (en) 2010-08-26 2013-12-23 애브비 인코포레이티드 Dual variable domain immunoglobulins and uses thereof
WO2012142391A1 (en) 2011-04-15 2012-10-18 Merck Patemt Gmbh Anti- il-1r1 inhibitors for use in cancer
EP2731971A1 (en) 2011-07-12 2014-05-21 Universität Zürich MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
DE102011083595A1 (en) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition of the effect of interleukin 1 beta for the treatment of endometriosis
BR112014007253A2 (en) 2011-09-30 2017-03-28 Novartis Ag use of antibodies that bind to il-1beta
AP2014007680A0 (en) 2011-12-02 2014-06-30 Novartis Ag Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
JP6342812B2 (en) 2011-12-14 2018-06-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Compositions and methods for diagnosing and treating iron-related disorders
US9580501B2 (en) 2011-12-16 2017-02-28 Synthon Biopharmaceuticals B.V. Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
TW201333035A (en) 2011-12-30 2013-08-16 Abbvie Inc Dual specific binding proteins directed against IL-13 and/or IL-17
JP6383665B2 (en) 2012-02-13 2018-08-29 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ IL-1β neutralizing human monoclonal antibody
CN103588878A (en) * 2012-08-15 2014-02-19 江苏泰康生物医药有限公司 Humanized anti-human-interleukin-1[belta] monoclonal antibody, preparation thereof and applications thereof
RU2017137740A (en) 2012-11-01 2019-02-11 Эббви Инк. ANTI-VEGF / DLL4-IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATIONS
KR102345999B1 (en) * 2012-11-05 2021-12-30 델레넥스 쎄라퓨틱스 아게 Binding members to il-1 beta
EP2919811B1 (en) 2012-11-16 2018-12-26 Novartis AG Use of il-1beta binding antibodies for treating peripheral arterial disease
EP2931750B8 (en) 2012-12-17 2021-11-03 Cell Medica Inc. Antibodies against il-1 beta
UY35195A (en) 2012-12-18 2014-07-31 Novartis Ag COMPOSITIONS AND METHODS FOR PROLINED ACTION PROTEINS
BR112015023797A2 (en) 2013-03-15 2017-10-24 Abbvie Inc dual specificity binding proteins directed against il-1b and / or il-17
WO2015083120A1 (en) 2013-12-04 2015-06-11 Novartis Ag USE OF IL-1β BINDING ANTIBODIES
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
WO2016008851A1 (en) * 2014-07-14 2016-01-21 Boehringer Ingelheim International Gmbh Anti-il-1b antibodies
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
TN2017000129A1 (en) 2014-10-14 2018-10-19 Dana Farber Cancer Inst Inc Antibody molecules to pd-l1 and uses thereof
BR112017009764A2 (en) 2014-11-10 2018-02-20 Hoffmann La Roche bispecific antibodies and methods of use in ophthalmology
SG11201703458UA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Anti-ang2 antibodies and methods of use
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3303388A1 (en) 2015-06-04 2018-04-11 Novartis AG Use of il-1 beta binding antibodies to treat peripheral arterial disease
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
JP6878405B2 (en) 2015-07-29 2021-05-26 ノバルティス アーゲー Combination therapy with antibody molecule against PD-1
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
JP2019503349A (en) 2015-12-17 2019-02-07 ノバルティス アーゲー Antibody molecules against PD-1 and uses thereof
EP3426775A1 (en) 2016-03-10 2019-01-16 Novartis AG Chemically modified messenger rna's
AU2017298656A1 (en) 2016-07-21 2019-02-07 Novartis Ag Use of the IL-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis
AU2017370942A1 (en) 2016-12-07 2019-06-13 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US20200315540A1 (en) 2016-12-14 2020-10-08 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
UY37758A (en) 2017-06-12 2019-01-31 Novartis Ag METHOD OF MANUFACTURING OF BIESPECTIFIC ANTIBODIES, BISPECTIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES
AU2018287519B2 (en) 2017-06-22 2021-07-22 Novartis Ag IL-1beta binding antibodies for use in treating cancer
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
EP3655961A4 (en) * 2017-07-17 2021-09-01 Massachusetts Institute of Technology Cell atlas of healthy and diseased barrier tissues
US20200239564A1 (en) 2017-08-25 2020-07-30 Novartis Ag Use of canakinumab
RU2020113234A (en) * 2017-09-13 2021-10-13 Новартис Аг APPLICATION OF IL-1β BINDING ANTIBODIES FOR TREATMENT OF ALCOHOLIC HEPATITIS
CA3081602A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
JP2021523894A (en) * 2018-05-09 2021-09-09 ノバルティス アーゲー Use of canakinumab
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
GB2575853A (en) * 2018-07-25 2020-01-29 Robert Wotherspoon Hugh IL-1ß binding antibody
CN110818793A (en) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 Antibodies against IL-1 β, pharmaceutical compositions thereof and uses thereof
WO2020039401A1 (en) 2018-08-24 2020-02-27 Novartis Ag Treatment comprising il-1βeta binding antibodies and combinations thereof
CN113383016B (en) * 2018-11-07 2022-09-13 三生国健药业（上海）股份有限公司 Antibodies that bind human IL-1beta, methods of making, and uses thereof
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
KR20210106437A (en) 2018-12-20 2021-08-30 노파르티스 아게 Dosage regimens and pharmaceutical combinations comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
GB201901187D0 (en) 2019-01-29 2019-03-20 Autolus Ltd Treatment of neurotoxicity and/or cytokine release syndrome
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924054A1 (en) 2019-02-15 2021-12-22 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20230020548A1 (en) 2019-12-09 2023-01-19 Novartis Ag Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
TWI793503B (en) 2020-01-20 2023-02-21 美商美國禮來大藥廠 ANTI-IL-1β ANTIBODIES
US20230220065A1 (en) * 2020-06-16 2023-07-13 Academia Sinica Antibodies to interleukin-1beta and uses thereof
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
WO2022167916A1 (en) 2021-02-03 2022-08-11 Novartis Ag Use of il-1b binding antibodies for treating neuroinflammatory disorders
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES
JP2024519893A (en) 2021-05-24 2024-05-21 ノバルティス アーゲー How to Treat Osteoarthritis
JP2023535884A (en) 2021-06-22 2023-08-22 ノバルティス アーゲー Bispecific antibody for use in treating hidradenitis suppurativa

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US534858A (en) * 1895-02-26 Workman s time-recorder
CA1172789A (en) 1980-09-25 1984-08-14 Hideo Kasahara POLYMERIC MATERIAL COMPRISING A POLYAMIDE BONDED TO A COPOLYMER CONTAINING AN IMIDE OF AN .alpha.,.beta. UNSATURATED CARBOXYLIC ACID
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
DE3785186T2 (en) 1986-09-02 1993-07-15 Enzon Lab Inc BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN.
DK590387A (en) * 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd ANTIBODIES AGAINST INTERLEUKIN-1
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
DE68925935T2 (en) 1988-10-01 1996-08-14 Otsuka Pharma Co Ltd Antibodies against interleukin-1 beta
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2640146B1 (en) 1988-12-08 1993-12-24 Commissariat A Energie Atomique ANTI-INTERLEUKIN MONOCLONAL ANTIBODIES 1 (ALPHA) AND 1 (BETA), THEIR PRODUCTION METHOD AND APPLICATIONS OF SAID ANTIBODIES TO DETECTION OF INTERLEUKINS 1 (ALPHA) AND 1 (BETA) AND THERAPEUTICS
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
DE69133476T2 (en) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgenic mice capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3714683B2 (en) 1992-07-30 2005-11-09 生化学工業株式会社 Anti-rheumatic agent
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2518295C2 (en) * 2005-06-21 2014-06-10 Ксома Текнолоджи Лтд. IL-1beta-BINDING ANTIBODIES AND FRAGMENTS THEREOF

Similar Documents

Publication Publication Date Title
RU2003107564A (en) ANTIBODIES TO HUMAN IL-1BETA
RU2002121649A (en) Recombinant Antibodies to Human Interleukin 1β
RU2003100512A (en) ANTIBODIES TO HUMAN MCP-1
CA2420231A1 (en) Antibodies to human il-1.beta.
JP7337204B2 (en) Single chain variable fragment CD3 binding protein
RU2007108067A (en) ANTAGONISTIC ANTIBODIES TO IL-17
JP5632744B2 (en) High affinity human antibodies to human nerve growth factor
RU2421464C2 (en) Human il-13 antibodies and their therapeutic application
RU2495050C2 (en) Gm-csf receptor binder
RU96115107A (en) "HUMAN" ANTIBODIES AND THEIR USE
JP2007097598A5 (en)
RU2008120625A (en) NEW USE OF IL-1β COMPOUNDS
RU2019123613A (en) BISPECIFIC ANTIGENBINDING MOLECULES CONTAINING ANTIBODY K4-1BB, CLONE 20N4.9
RU2003126168A (en) THERAPEUTIC BINDING MOLECULES
US20050004353A1 (en) Human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors
JP2004502421A5 (en)
RU2008129080A (en) MEANS AND METHODS FOR TREATING TUMOR DISEASES
RU2006115835A (en) HUMAN ANTIBODIES AGAINST HUMAN 4-1BB (CD137)
JP2003523764A5 (en)
CN107001468A (en) CD3 binding structural domains
RU2012107286A (en) HIGH-AFFINITY HUMAN ANTIBODIES TO HUMAN ANGIOPOETIN-2
RU2009126723A (en) ANTIBODIES TO OX40L
RU2009149294A (en) ANTIGEN BINDING PROTEINS AIMED AT ORF0657N S.AUREUS
JP2006512899A5 (en)
RU2009136913A (en) BISPECIFIC BINDING AGENTS WITH INTER-SPECIFIC SPECIFICITY